Rare-disease specialist Catalyst Pharmaceuticals is set to be acquired by healthcare group Angelini Pharma in a $4.1 billion deal. Angelini will pay $31.50 for each of Nasdaq-listed Catalyst’s ...
With an eye on the lucrative U.S. market, Italy’s Angelini Pharma will acquire rare disease specialist Catalyst Pharmaceuticals and its potential blockbuster, Firdapse, for $4.1 billion. Rome-based ...
If you have an AMD graphics card, then you need the AMD Catalyst Control Center which is a part of the AMD Catalyst software engine that provides customization options to manage display settings.
State-backed CDP Equity to have a stake in combined entity Deal comes after Chiesi's $1.9 billion buyout of U.S. KalVista Angelini aims to create global player in rare disease drugs ROME/MILAN, May 7 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results